Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, Monica Di Battista, Giovenzio Genestreti, Santino Minichillo, Antonella Mura, Stefania Bartolini, Raffaele Agati, Alba A. Brandes

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Standard glioblastoma therapy is long-lasting. Among second-line therapy, choices could be bevacizumab and nitrosoureas depending on National Agencies approval. There is no consensus on 3rd line therapy or clinical trials specifically designed for this setting. Methods: We reviewed our institutional database on all consecutive patients who received 3rd line therapy for glioblastoma. Results: Data on 168 out of 1337 (12.6%) glioblastoma patients who underwent 3rd line therapy treatment were collected. Third line treatments were bevacizumab or chemotherapy (nitrosourea, temozolomide or carboplatin plus etoposide). Median progression free survival was 2.9 months and median survival time was 6.6 months from the start of 3rd line therapy. Bevacizumab significantly improved progression-free survival (4.7 vs. 2.6 months, p =.020) and survival from 3rd line start (8.0 vs. 6.0 months, p =.014) in respect to chemotherapy. Toxicity of grade ≥ 3 occurred in 13.7% of patients. In multivariate analysis, survival in 3rd line treatment depends on MGMT methylation (p =.006) and treatment with Bevacizumab (p =.011). Conclusions: Third line therapy in selected glioblastoma patients may be feasible and well tolerated. Bevacizumab improved outcome in 3rd line in respect to chemotherapy.

Original languageEnglish
Pages (from-to)383-388
Number of pages6
JournalJournal of Neuro-Oncology
Volume139
Issue number2
DOIs
Publication statusPublished - Sep 1 2018

Keywords

  • Bevacizumab
  • Brain neoplasms
  • Glioblastoma
  • MGMT
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?'. Together they form a unique fingerprint.

Cite this